Dabigatran etexilate Biocon 75 mg hard capsules

Χώρα: Μάλτα

Γλώσσα: Αγγλικά

Πηγή: Medicines Authority

Διαθέσιμο από:

Biocon Pharma Malta Limited The Victoria Centre Unit 2 Lower Ground Floor Valletta Road Mosta MST 9012 , Malta

Φαρμακολογική κατηγορία (ATC):

B01AE07

INN (Διεθνής Όνομα):

DABIGATRAN ETEXILATE 75 mg

Φαρμακοτεχνική μορφή:

HARD CAPSULE

Σύνθεση:

DABIGATRAN ETEXILATE 75 mg

Τρόπος διάθεσης:

POM

Θεραπευτική περιοχή:

ANTITHROMBOTIC AGENTS

Καθεστώς αδειοδότησης:

Authorised

Ημερομηνία της άδειας:

2024-03-11

Φύλλο οδηγιών χρήσης

1
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
DABIGATRAN ETEXILATE BIOCON 75 MG HARD CAPSULES
dabigatran etexilate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm
them, even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Dabigatran etexilate Biocon is and what it is used for
2.
What you need to know before you take Dabigatran etexilate Biocon
3.
How to take Dabigatran etexilate Biocon
4.
Possible side effects
5.
How to store Dabigatran etexilate Biocon
6.
Contents of the pack and other information
1.
WHAT DABIGATRAN ETEXILATE BIOCON IS AND WHAT IT IS USED FOR
Dabigatran etexilate Biocon contains the active substance dabigatran
etexilate and belongs to a group
of medicines called anticoagulants. It works by blocking a substance
in the body which is involved in
blood clot formation.
Dabigatran etexilate Biocon is used in adults to:
-
prevent the formation of blood clots in the veins after knee or hip
replacement surgery.
Dabigatran etexilate Biocon is used in children to:
-
treat blood clots and to prevent blood clots from reoccurring.
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE DABIGATRAN ETEXILATE BIOCON
DO NOT TAKE DABIGATRAN ETEXILATE BIOCON
-
if you are allergic to dabigatran etexilate or any of the other
ingredients of this medicine (listed
in section 6).
-
if you have severely reduced kidney function.
-
if you are currently bleeding.
-
if you have a disease in an organ of the body that increases the risk
of serious bleeding (e.g.,
stomach ulcer, injury or bleeding in the brain, recent surgery of the
brain or eyes).
-
if you have an increased tendenc

Αρχείο Π.Χ.Π.

1
1.
NAME OF THE MEDICINAL PRODUCT
Dabigatran etexilate Biocon 75 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each hard capsule contains 86.48 mg of dabigatran etexilate (as
mesilate) equivalent to 75 mg of
dabigatran etexilate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsule.
Off white to pale yellow coloured pellets filled in white to off white
hard capsule size 2 (approx.
18.0 mm).
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Primary prevention of venous thromboembolic events (VTE) in adult
patients who have undergone
elective total hip replacement surgery or total knee replacement
surgery.
Treatment of VTE and prevention of recurrent VTE in paediatric
patients from birth to less than 18
years of age.
For age appropriate dose forms, see section 4.2.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Dabigatran etexilate Biocon capsules can be used in adults and
paediatric patients aged 8 years or
older who are able to swallow the capsules whole.
There are other age appropriate dose forms for the treatment of
children below 8 years.
When changing between the formulations, the prescribed dose may need
to be altered. The dose
stated in the relevant dosing table of a formulation should be
prescribed based on the weight and age
of the child.
_PRIMARY PREVENTION OF VTE IN ORTHOPAEDIC SURGERY _
_ _
The
recommended
doses
of
dabigatran
etexilate
and
the
duration
of
therapy
for
primary
prevention of VTE in orthopaedic surgery are shown in table 1.
2
TABLE 1:
DOSE RECOMMENDATIONS AND DURATION OF THERAPY FOR PRIMARY PREVENTION OF
VTE
IN ORTHOPAEDIC SURGERY
TREATMENT
INITIATION
ON
THE
DAY OF SURGERY 1-
4
HOURS
AFTER
COMPLETED
SURGERY
MAINTENANCE
DOSE STARTING ON
THE
FIRST
DAY
AFTER SURGERY
DURATION
OF
MAINTENANCE DOSE
Patients
following
elective
knee
replacement surgery
single capsule of
110 mg
dabigatran
etexilate
220 mg
dabigatran
etexilate once
daily taken as 2
capsules of 110
mg
10 days
Patients
following
elective
hip
replacement surgery
28-35 days
_DOSE RED